Open AccessSmell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study
Author(s) -
B Barroso,
M Valverde-Monge,
I Alobid,
J M Olaguibel,
Manuel Jorge Rial,
S Quirce,
E Arismendi,
P Barranco,
D Betancor,
I Bobolea,
Blanca Cárdaba,
María Jesús Cruz,
E Curto,
J Domínguez-Ortega,
F J González-Barcala,
C Martínez-Rivera,
I Mahíllo-Fernández,
X Muñoz,
C Picado,
V Plaza,
José Manuel RodrigoMuñoz,
L Soto-Retes,
A Valero,
V Del Pozo,
J Mullol,
J Sastre
Publication year - 2022
Publication title -
journal of investigational allergology and clinical immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.657
H-Index - 61
eISSN - 1698-0808
pISSN - 1018-9068
DOI - 10.18176/jiaci.0812
Subject(s) - medicine , mepolizumab , hyposmia , omalizumab , olfaction , asthma , benralizumab , nasal polyps , anosmia , immunology , immunoglobulin e , disease , eosinophil , antibody , covid-19 , infectious disease (medical specialty) , neuroscience , biology
Chronic rhinosinusitis with nasal polyps (CRSwNP), which is characterized by partial loss of smell (hyposmia) or total loss of smell (anosmia), is commonly associated with asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). CRSwNP worsens disease severity and quality of life. The objective of this real-world study was to determine whether biological treatments prescribed for severe asthma can improve olfaction in patients with CRSwNP. A further objective was to compare the improvement in in olfaction in N-ERD and non-N-ERD subgroups.